A novel feedback loop between high MALAT-1 and low miR-200c-3p promotes cell migration and invasion in pancreatic ductal adenocarcinoma and is predictive of poor prognosis

Meng Zhuo†, Cuncun Yuan†, Ting Han†, Jiujie Cui†, Feng Jiao* and Liwei Wang*
Background
Pancreatic ductal adenocarcinoma (PDAC) is considered to be one of the most lethal tumor worldwide [1] and will become the second leading cause of tumor-associated mortality in the USA by 2030 [2]. In spite of rapid progress in understanding PDAC tumorigenesis at the molecular level and therapeutic approaches, the prognosis of PDAC remains poor, with a 5-year survival rate less than 5% [3]. PDAC is insensitive to chemotherapy and radiotherapy, meaning the identification of novel therapeutic targets is imperative.

Non-coding RNAs (ncRNAs) are not transcribed and translated into coding-proteins, including micro-RNAs (miRNAs) and long non-coding RNAs (lncRNAs) [4]. LncRNAs have attracted increasing attention in recent years due to important biological effects in carcinogenesis and progression [5, 6]. In recent years, a large number of lncRNAs, such as MALAT-1, HOTAIR, H19 and PVT1 appear to play important roles in PDAC development, as it regulates cell growth, progression and chemo-resistance, etc. [7]. We have previously found that the MALAT-1 promotes tumor growth and metastases in PDAC [8, 9]. However, the underlying molecular mechanisms still need to be further clarified.

Recently interaction research between lncRNAs and miRNAs is attracting an increasing amount of attention [10]. In this study, we revealed a reciprocal suppression between MALAT-1 and miR-200c-3p expression in PDAC, and performed underlying mechanisms analysis.

Methods

Ethics statement
The present study was approved and supervised by the Ethics Committee of the Renji Hospital, School of Medicine, Shanghai Jiaotong University. Written informed consent was obtained from all subjects.

Patients and samples
Sixty-five paraffin embedded samples were collected from the Surgery Department, Renji Hospital, School of Medicine, Shanghai Jiaotong University from January 2009 to December 2012, and were histopathologically confirmed and staged in accordance with the Union for International Cancer Control. The follow-up data was ended in December, 2017.

Cell culture
Human pancreatic ductal cells (HPDE) and PDAC cell lines SW1990, Capan-1, HS-766 T, CFPAC-1, BxPC-3, AsPC-1 and PANC-1 were all obtained from Chinese Academy of Sciences Cell Bank (Shanghai, China). SW1990 cell was cultured in L-15 medium supplemented with 10% fetal bovine serum (FBS, all purchased from Gibco, Grand Island, NY, USA), and grown in room temperature air. The other cells were cultured in RPMI 1640 supplemented with 10% FBS (all purchased from Gibco, Grand Island, NY, USA), grown at 37 °C in 5% CO₂ saturated humidity.

RNA extraction and reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR)
The miRNeasy FFPE Kit (QIAGEN, Hilden, Germany) kit and miniBEST universal RNA extraction kit (Takara Bio, Dalian, China) was used to extract total RNA from tissue samples and cultured cells, respectively. Reverse transcription and RT-qPCR kits were employed to examine MALAT-1 and miR-200c-3p level. RT-qPCR reactions were performed by the ViiATM 7 system (Applied Biosystems Inc. Foster City, CA, USA). The primers used in the reaction for MALAT-1, miR-200c-3p, ZEB1, GAPDH and U6 were purchased from Tiangen (Tiangen, Beijing, China). GAPDH and U6 were detected as the endogenous control to normalize the expression levels of the different genes. Comparative threshold cycle (Ct) ($2^{-\Delta\Delta Ct}$) method was selected to calculate relative expression.

Cell proliferation assay
Cell proliferation was measured via the sulforhodamine B assay. Cells were seeded in 96-well plates and transfected with miR-200c-3p nc, miR-200c-3p inhibitor, or mimics and cultured for 24, 48, 72, and 96 h. Using microtiter plate reader (VERSMax), optical density (OD) values were measured at 560 nm.

Cell migration and invasion assays
Invasion assays were conducted 24 h after transfection. Briefly, 1 × 10⁵ cells in serum-free media were seeded into the upper chamber of an insert (8.0 μm, Millipore, Billerica, MA, USA) that was coated with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) [9]. Then, 10% FBS-containing medium was placed in the lower chambers of the insert. After incubation for 24 h, the invaded cells were fixed and stained using 0.1% crystal violet staining solution. Finally, the cells were counted by a microscope at a magnification of × 200 in five randomly selected fields. Migration assays were similar to the above-mentioned assay but no Matrigel was used.

RNA binding protein immunoprecipitation (RIP)
RIP assay was performed by the Magna RIP™RNA-Binding Protein Immunoprecipitation Kit (Millipore, Billerica, MA, USA). Cells were lysed in RIP Lysis Buffer. MiR-200c-3p and MALAT-1 were immunoprecipitated with AGO2 antibodies. The complexes that bound on the magnetic beads were immobilized and unbound materials were washed off. Then, miR-200c-3p and MALAT-1 were extracted and analyzed by RT-qPCR.
Luciferase assays
Firstly, 293 T cells were seeded in 24-well plates and transfected with 50 nM miR-200c-3p mimics or miR-200c-3p nc respectively. Secondly, after 24 h transfection, the above 293 T cells were then transfected with 100 ng luciferase reporter vectors that contained either wild-type (MALAT-1-wt) or mutant types (MALAT-1-mut) (both were designed and structured from Obio Technology, Shanghai, Corp. Ltd). The Renilla luciferase reference plasmid was included in each transfection system as an internal control to normalize the transfection efficiency. Finally, at 48 h after transfection, the Dual-Luciferase Reporter Assay using an illuminometers (Promega Corporation, Madison, WI) was performed according to the manufacturer’s protocol.

Western blot analysis
Western blot analysis was conducted as previously described [11]. The primary antibodies were as follows: anti-AGO2 (1:1000), anti-ZEB1 (1:1000, Cell Signaling Technology, Beverly, MA, USA), and anti-β-Actin (1:2500, Santa Cruz Biotechnology, Santa Cruz, CA, USA).

Plasmid construction and transfection
Recombinant plasmid pcDNA3.0/ZEB1, miR-200c mimic, miR-200c inhibitor, siRNA against MALAT-1, and negative controls were all obtained or constructed from GenePharma (Shanghai, China). The detail sequences were under Additional file 1. Lipofectamine 2000 (Invitrogen, USA) was used as transfections agents.

Statistical analyses
Data were presented as the mean ± SE. All statistical analyses were conducted by SPSS statistical software 17.0 (SPSS Inc., Chicago, IL, USA). For comparison between two groups, we used two-tailed Student’s t test. Multiple group comparisons were calculated with one-way ANOVA analysis. Least-significant difference (LSD) was used for post hoc test. χ² tests or Fisher’s exact methods was used to detect correlation between MALAT-1 level or miR-200c-3p and clinical characteristics, as appropriate. The correlation between MALAT-1, miR-200c-3p and ZEB1 expression was analyzed using Pearson Correlation. Kaplan-Meier method was used to estimate overall survival (OS). Univariate and multivariate COX regression analysis was performed. *P < 0.05 was considered to indicate a statistically significant difference.

Results
Elevated level of MALAT-1 inhibits miR-200c-3p expression in PDAC
To investigate the interaction among potential miRNAs and MALAT-1, we used the Starbase v2.0 (starbase.sysu.edu.cn LncRNA.php) to search for miRNAs that complementarily base-pair with MALAT-1. Twenty miRNAs were predicted to bind to MALAT-1 (see Additional file 2). We further validated 20 miRNAs expression after knockdown of MALAT-1 in CFPAC-1 and AsPC-1 cell lines, which showed relative high level of MALAT-1 (Fig. 1a and b). Initial profiling identified three miRNAs (miR-200c-3p, miR-92b-3p, and miR-181c-5p) that exhibited > 2-fold-change compared with the control (Fig. 1c and d; *P < 0.05). Next, miR-200c-3p was chosen for the study because it showed the greatest fold-change in response to the MALAT-1 knockdown.

Anti-miR-200c-3p restores MALAT-1-siRNA function
Subsequently, to study the biological function of miR-200c-3p on PDAC, we transfected AsPC-1 and CFPAC-1 cells with miR-200c-3p nc, inhibitors, or mimics (Fig. 2a; *P < 0.05). Sulforhodamine B assay showed that there were no differences of cell proliferation ability in different groups, including miR-200c-3p nc, inhibitors, or mimics group (Fig. 2b; *P < 0.05). Transwell assay revealed that miR-200c-3p mimics transfection decreased the number of migrating cells in comparisons with that of miR-200c-3p nc, while transfection of miR-200c-3p inhibitor increased the number of migrating cells (Fig. 2c; *P < 0.05). Taken together, miR-200c-3p suppressed cell migration and invasion in PDAC, but not cell proliferation.

Our previous studies have revealed that MALAT-1 promotes tumor growth and metastases in PDAC [8, 9]. To further examine if the effects of MALAT-1 on cell migration and invasion were partially mediated by miR-200c-3p, we co-transfected CFPAC-1 and AsPC-1 cells with MALAT-1 siRNA and miR-200c-3p inhibitor. The results revealed that knockdown of MALAT-1 suppressed cell migration and invasion, whereas miR-200c-3p inhibition partially reversed decreased invasive-ness (Fig. 3a and b; *P < 0.05). These findings were also confirmed in PANC-1 and CAPAN-1 cell lines (see Additional file 3; *P < 0.05). Together, the data suggested that miR-200c-3p can partially rescue the loss of MALAT-1-mediated PDAC cell migration and invasion.

MALAT-1 upregulates ZEB1 expression by sponging miR-200c-3p
Among the many targets of miR-200c-3p, we focused on ZEB1 because it encodes a zinc finger and homeodomain transcription factor proteins that function in PDAC metastasis. Firstly, the result verified that the miR-200c-3p inhibitor triggered significant endogenous ZEB1 expression, whereas miR-200c-3p overexpression silenced ZEB1 protein expression (Fig. 4a; *P < 0.05). Furthermore, cotransfection with MALAT-1 siRNA and miR-200c-3p inhibitor revealed that the miR-200c-3p inhibitor weakened down-regulation of ZEB1 by MALAT-1 knockdown (Fig. 4b; *P < 0.05). Further study
showed that ZEB1 overexpression can rescue the loss of MALAT-1-mediated repression activity in PDAC, including reduced cell migration and invasion (Fig. 5a, b, c and d; \( P < 0.05 \)). This experimental evidence supported that the observed migration/invasion defect in MALAT-1 knockdown or miR200c-3p mimics was in fact mediated via regulation of ZEB1 expression.

**MALAT-1 was a target of miR-200c-3p**

We then measured MALAT-1 expression levels in response to transfection of miR-200c-3p mimic or inhibitor. The results showed that inhibiting miR-200c-3p up-regulated MALAT-1 levels (Fig. 6a; \( P < 0.05 \)), whereas miR-200c-3p overexpression significantly decreased MALAT-1 in both cell lines (Fig. 6b; \( P < 0.05 \)). The data above implicated MALAT-1 was also a target of miR-200c-3p.

**MALAT-1 and miR-200c-3p are associated with immunoprecipitated AGO2 complex**

AGO2 is necessary for miRNA-mediated gene silencing [12]. To investigate whether MALAT-1 expression is controlled by miR-200c-3p, we knocked down AGO2 in AsPC-1 and CFPAC-1 (Fig. 7a; \( P < 0.05 \)). As expected, MALAT-1 expression was increased in AGO2-knockdown cells (Fig. 7b; \( P < 0.05 \)). Also, the stability of miR-200c-3p was significantly impaired in AGO2-knockdown cells.
These data collectively suggest that miR-200c-3p directly regulates MALAT-1 levels. To further study the mechanism that underlies the negative regulation of miR-200c-3p by MALAT-1 and to obtain evidence that supports a potential interaction between these two genes, we used Starbase v2.0 to predict the interaction sites between miR-200c-3p and MALAT-1 (Fig. 7d), and cloned the two mutated binding sites to vector, respectively. The mutants were designated as pMALAT-1-mut1 and pMALAT-1-mut2 (Fig. 7d). Then, luciferase assays were performed in 293FT cells that were transfected with pMALAT-1-mut1 or pMALAT-1-mut2. The results showed that luciferase activity decreased in the pMALAT-1 WT group in 293T-transfected miR-200c-3p mimics compared to control group (Fig. 7e; \( P < 0.05 \)). However, there were no effects on the luciferase reporter activities of pMALAT-1 mut-1 and pMALAT-1 mut-2 (Fig. 7e; \( P < 0.05 \)). Collectively, these results suggested that MALAT-1 was a direct target gene of miR-200c. Further, AGO2 RIP assay showed that transfection with miR-200c-3p mimics enriched MALAT-1 and miR-200c-3p in AGO2 immunoprecipitated from AsPC-1 (Fig. 7f; \( P < 0.05 \)) and CFPAC-1 (Fig. 7g; \( P < 0.05 \)) cell extracts. Collectively, these results were consistent with the hypothesis that MALAT-1 stability is AGO2-dependent and is regulated by miR-200c-3p in PDAC.

MALAT-1 expression is negatively associated with miR-200c-3p in PDAC tissues

We further evaluated the correlation between MALAT-1 and miR-200c-3p expression and the clinicopathological characteristics. The median value was used as cut-off to divide MALAT-1 or miR-200c-3p expression into low level group (\( n = 33 \)) and high level group (\( n = 32 \)). As shown in Additional file 4, MALAT-1 expression is strongly correlated with lymph node metastasis (\( P = 0.007 \)) and clinical stage (\( P = 0.007 \)). And miR-200c-3p expression was negatively correlated with gender (\( P = 0.011 \)), lymph node metastasis (\( P = 0.017 \)), and clinical stage (\( P = 0.017 \)). Bivariate correlation analysis showed that expression of MALAT-1 and ZEB1 was negatively correlated with miR-200c-3p transcript level of PDAC tissues (Fig. 8a; \( P < 0.05 \)). There was a positive correlation between MALAT-1 and ZEB1 level (Fig. 8a; \( P < 0.05 \)). And this phenomenon was consistent at different clinical stages (Fig. 8b and c; \( P < 0.05 \)).

Association between MALAT-1 and miR-200c-3p expression and prognosis in PDAC patients

Kaplan-Meier analysis showed that patients with PDAC tumors expressing high MALAT-1 levels had significantly lower OS than those expressing low MALAT-1
MALAT-1 upregulates ZEB1 expression by sponging miR-200c-3p.

(a) The protein levels of ZEB1 were detected in response to transfection of miR-200c-3p nc, inhibitors, or mimics. The result showed that transfection of miR-200c-3p inhibitor triggered significant endogenous ZEB1 expression compared to that of nc in AsPC-1 and CFPAC-1 cells, whereas miR-200c-3p mimic silenced ZEB1 protein expression.

(b) Western blot was performed to examine ZEB1 protein expression in AsPC-1 and CFPAC-1 after co-transfection with MALAT-1 siRNA and miR-200c-3p inhibitor. Cotransfection with MALAT-1 siRNA and miR-200c-3p inhibitor showed that the miR-200c-3p inhibitor weakened the down-regulation of ZEB1 by MALAT-1 knockdown. β-actin was used as an internal control for protein loading. Relative densities are presented as the fold change relative to the internal control.

**Fig. 4** MALAT-1 upregulates ZEB1 expression by sponging miR-200c-3p. a The protein levels of ZEB1 were detected in response to transfection of miR-200c-3p nc, inhibitors, or mimics. The result showed that transfection of miR-200c-3p inhibitor triggered significant endogenous ZEB1 expression compared to that of nc in AsPC-1 and CFPAC-1 cells, whereas miR-200c-3p mimic silenced ZEB1 protein expression. b Western blot was performed to examine ZEB1 protein expression in AsPC-1 and CFPAC-1 after co-transfection with MALAT-1 nc/si1 or miR-200c-3p nc/inhibitor. Cotransfection with MALAT-1 siRNA and miR-200c-3p inhibitor showed that the miR-200c-3p inhibitor weakened the down-regulation of ZEB1 by MALAT-1 knockdown. β-actin was used as an internal control for protein loading. Relative densities are presented as the fold change relative to the internal control.

**Fig. 3** Anti-miR-200c-3p restores MALAT-1-siRNA function. a, b Transwell migration assays were employed to detect cell migration ability when co-transfected AsPC-1 (a) and CFPAC-1 (b) cells with MALAT-1 siRNA and miR-200c inhibitor. The results demonstrated that MALAT-1 knockdown inhibited the migration and invasion of pancreatic cancer cells, whereas miR-200c-3p inhibition partially reversed decreased invasiveness.
whereas that patients expressing high miR-200c-3p levels had significantly higher OS than those expressing low miR-200c-3p (Fig. 9b; \( P < 0.001 \)). To further investigate the correlation of OS with MALAT-1 and miR-200c-3p expression, the results showed that MALAT-1 (high)/ miR-200c-3p (low) associated with shorter OS of PDAC patients (Fig. 9c; \( P < 0.001 \)).

Using univariate analysis, in addition to clinical stage, both MALAT-1 (\( P < 0.001 \)) and miR-200c-3p (\( P < 0.001 \)) levels were closely associated with OS (see Additional file 5). Multivariate analysis revealed that both MALAT-1 (\( P < 0.001 \)) and miR-200c-3p (\( P < 0.001 \)) level was an independent prognostic factor for PDAC patients (see Additional file 5).

**Discussion**

Gathering evidence demonstrated that lncRNAs occupies an important position in cancer pathogenesis [4, 13]. Previously, we have outlined the functional lncRNAs in PDAC, such as MALAT-1, HOTAIR, H19 and HULC, and decipher possible mechanisms of lncRNAs [7]. MALAT-1, one of the first lncRNAs, was demonstrated to be associated with lung cancer [14]. Also, MALAT-1 has been linked to several other human tumor entities [15, 16]. In our previous studies, we have found that the MALAT-1 served as oncogenic lncRNA participating in PDAC cell growth and progression [8, 9]. However, the underlying molecular mechanisms are far from being fully elucidated.

Amounting studies indicate that MALAT-1 could exert functions by targeting miRNAs. Han X et al. [17] found that MALAT-1 modulated Srf through miR-133 and discovered a novel correlation among MALAT-1, miR-133, and Srf in myoblast differentiation. Lei R et al. [18] revealed that high level of MALAT-1 promoted cell growth by targeting miR-506 in ovarian cancer. In our study, we found that MALAT-1 knockdown decreased the expression of miR-200c-3p in PDAC. On the other
MALAT-1 was a target of miR-200c-3p. a, b RT-qPCR was used to measure MALAT-1 expression levels in response to transfection of miR-200c-3p nc, mimic or inhibitor. The results showed that inhibiting miR-200c-3p up-regulated MALAT-1 levels (a), whereas miR-200c-3p overexpression significantly decreased MALAT-1 in both cell lines (b).

MALAT-1 and miR-200c-3p are associated with the immunoprecipitated AGO2 complex. a Western blot was employed to detect AGO2 expression after AGO2 knockdown in AsPC-1 and CFPAC-1 cells. b, c RT-qPCR was use to examine MALAT-1 (b) and miR-200c-3p (c) levels in response to knockdown of AGO2 in AsPC-1 and CFPAC-1, respectively. d Binding sites for miR-200c-3p in MALAT-1, as predicted by Starbase v2.0. The parts in the column imply the possible binding sites in MALAT-1. e Seed matches from MALAT-1 wt or its mutants (MALAT-1-mut-1 and MALAT-1-mut-2) that were devoid of specific miR-200c-3p-binding sites were mutagenized and transfected into 293 T cells together with 50 nM of miR-200c-3p mimics or nc. MiR-200-3p mimics significantly decreased luciferase activity only in the MALAT-1-wt construct. f, g RIP with monoclonal anti-Ago2 and IgG from AsPC-1 (f) and CFPAC-1 (g) cell extracts transfected with nc or miR-200c-3p mimics. Levels of MALAT-1 and miR-200c-3p were measured by RT-qPCR.
Fig. 8 Correlation between MALAT-1, miR-200c-3p and ZEB1 expression in PDAC patients. a Pearson correlation analysis showed that expression of MALAT-1 and ZEB1 was negatively correlated with miR-200c-3p transcript level. And there was a positive correlation between MALAT-1 and ZEB1 level. b, c The phenomenon of correlation between MALAT-1, miR-200c-3p and ZEB1 were consistent at different clinical stages, including early (≤ II, a, b) and advanced stage (> II, c).

Fig. 9 Association between MALAT-1 and miR-200c-3p expression and prognosis in PDAC patients. a The log-rank test showed that patients with PDAC tumors expressing high MALAT-1 levels had significantly lower OS than those expressing low MALAT-1. b The patients expressing high miR-200c-3p levels had significantly higher OS than those expressing low miR-200c-3p. c The log-rank test showed that MALAT-1 (high)/miR-200c-3p (low) correlated with shorter OS of PDAC patients compared to that of other groups, including MALAT-1 (low)/miR-200c-3p (low), MALAT-1 (low)/miR-200c-3p (high) and MALAT-1 (high)/miR-200c-3p (high).
hand, miR-200c-3p mimic decreased the level of MALAT-1, while miR-200c-3p inhibitor upregulated MALAT-1 level. A luciferase assays further confirmed that MALAT-1 was a direct target of miR-200c-3p in PDAC.

Subsequently, we discussed the mechanism of such a feedback loop. It was found that MALAT-1 and miR-200c-3p bind to the same RNA-induced silencing complex. Based on the fact that lncRNAs act as ceRNA to bind specific miRNAs and regulate their function [19, 20]. We supposed that MALAT-1 may inhibit miR-200c-3p expression in such way in PDAC. It was found that MALAT-1 could upregulate ZEB1 expression, which was a target of miR-200c-3p. Together, the above results further confirm our hypothesis. For another, miRNAs regulate protein-coding gene expression at transcriptional level through binding to the 3′-untranslated regions [21, 22]. Leucci E et al. [23] found that miR-9 targeted the AGO2-mediated deregulation of MALAT-1 in the nucleus. Wang X et al. [24] showed that posttranscriptional inhibitory mechanism of MALAT-1 by miR-101 and miR-217 suppressed cell proliferation, migration, and invasion in esophageal squamous cell carcinoma. We proposed that the way that miR-200c-3p inhibited the level of MALAT-1 expression is in a way similar to miRNA-mediated silencing of protein-coding genes. Our data were consistent with recent report in ovarian cancer [12]. Hirata H et al. [25] found that MALAT-1 promoted aggressive phenotype by interacts with miR-205 and EZH2 in renal cell carcinoma. Our previous study had demonstrated that MALAT-1 could recruit EZH2 to the E-cadherin promoter, where it repressed E-cadherin expression, leading to cell migration and invasion in PDAC [26]. In this study, we revealed reciprocal suppression between MALAT-1 and miR-200c-3p expression and clarify the underlying mechanism.

Finally, we found that MALAT-1 and ZEB1 was negatively correlated with miR-200c-3p transcript level of PDAC tissues. And there was a positive correlation between MALAT-1 and ZEB1 level. Survival analysis reveals that both MALAT-1 and miR-200c-3p levels are independent prognostic factors. MALAT-1 (high)/miR-200c-3p (low) correlated with shorter OS for PDAC patients. Interestingly, Li Q et al. [27] showed that MALAT-1 levels were lower in most endometrioid endometrial carcinoma tissues than in normal tissues, while miR-200c-3p levels were higher. Therefore, different expression model of MALAT-1 and miR-200c-3p in human tumor entities needs further mechanism researches.

**Conclusion**

In summary, our findings firstly revealed a novel feedback loop between high MALAT-1 and low miR-200c-3p (Fig. 10). MALAT-1 could function as a miRNA sponge to attenuate miR-200c-3p function, leading to ZEB1 upregulation in PDAC. On the other hand, miR-200c-3p inhibited the level of MALAT-1 expression in a way similar to miRNA-mediated silencing of target genes. Targeting the feedback loop between high MALAT-1 and low miR-200c-3p will be a novel therapeutic strategy for PDAC.

**Additional files**

**Additional file 1:** The primer sequences of miR-200c mimic, miR-200c inhibitor, siRNA against MALAT-1, and their respective negative controls. (DOCX 15 kb)

**Additional file 2:** Initial profiling of miRNAs that have base-pairing with MALAT-1 in response to knockdown of MALAT-1. (DOCX 16 kb)

**Additional file 3:** Anti-miR-200c-3p restores MALAT-1-siRNA function in PANC-1 and CAPAN-1 cells. a, b. Transwell migration assays were employed to detect cell migration ability when co-transfected PANC-1 (a) and CAPAN-1 (b) cells with MALAT-1 siRNA and miR-200c inhibitor. (TIF 5830 kb)

**Additional file 4:** Correlation between the clinicopathologic characteristics and MALAT-1 and miR-200c-3p expression in PDAC (n = 65). (DOCX 21 kb)
Additional file 5: Summary of univariate and multivariate COX regression analysis of OS duration in all PDAC patients (n = 65). (DOCX 20 kb)

Abbreviations
FBS: Fetal bovine serum; HPDE: Human pancreatic ductal cells; IncRNAs: Long non-coding RNAs; LSD: Least-significant difference; MALAT-1: Metastasis-associated lung adenocarcinoma transcript 1; miRNAs: Micro-RNAs; ncRNAs: Non-coding RNAs; OD: Optical density; OS: Overall survival; PDAC: Pancreatic ductal adenocarcinoma; RIP: RNA binding protein immunoprecipitation; RT-qPCR: Reverse transcription quantitative real-time polymerase chain reaction

Acknowledgements
We sincerely appreciate the patients who participated in this study.

Funding
This study was supported by the National Natural Science Foundation of China (grant nos. 81502017 for Feng Jiao, 81502018 for Jujie Cui and 81572315 for Liwei Wang). The funding bodies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
The dataset supporting the conclusions of this article is available from the corresponding author on reasonable request.

Authors’ contributions
M2 and FJ carried out the cellular and histological studies, the statistical analysis, and drafted the manuscript. CY collected tumor tissues and followed up patients. TH and JC helped perform the cellular and histological studies. FJ and LW participated in designing the study. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved by the Research Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiaotong University. Written informed consent was obtained from all subjects.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Department of Oncology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, 160 Pujian Road, Shanghai 200127, China. 2 Department of Pathology, Eye Ear Nose and Throat Hospital, Fudan University, 83 Fenyang Road, Shanghai 200031, China.

Received: 2 May 2018 Accepted: 15 October 2018
Published online: 23 October 2018

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, Iver, and pancreas cancers in the United States. Cancer Res. 2014; 74:2013–21.
3. Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016; 388:73–85.
4. Khurana E, Fu Y, Chakravarty D, Demichels F, Rubin MA, Gerstein M. Role of non-coding sequence variants in cancer. Nat Rev Genet. 2016;17:93–108.
5. Huarte M. The emerging role of IncRNAs in cancer. Nat Med. 2015;21:1253–61.
6. Schmitt AM, Chang HY. Long non-coding RNAs in Cancer pathways. Cancer Cell. 2016;29:452–63.
7. Han T, Hu H, Zhuo M, Wang L, Cui JJ, Jiao F, et al. Long non-coding RNA: an emerging paradigm of pancreatic Cancer. Curr Mol Med. 2016;16:702–9.
8. Jiao F, Hu H, Han T, Yuan C, Wang L, Jin Z, et al. Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells. Int J Mol Sci. 2015;16:6677–93.
9. Jiao F, Hu H, Yuan C, Wang L, Jiang W, Jin Z, et al. Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer. Oncol Rep. 2014;32:2485–92.
10. Ragusa M, Barbagallo C, Brex D, Caponnetto A, Cimigliaro M, Battaglia R, et al. Molecular Crosstalking among noncoding RNAs: a new network layer of genome regulation in Cancer. Int J Genomics. 2017;2017:4723193.
11. Han T, Zhuo M, Hu H, Jiao F, Wang LW. Synergistic effects of the combination of 5-AzaCdr and suberylandilide hydroxamic acid on the anticancer property of pancreatic cancer. Oncol Rep. 2018;39:264–70.
12. Pa M, Naizera G, Seyiti A, Kuerbang G. Long noncoding RNA MALAT functions as a sponge of miR-200c in ovarian Cancer. Oncol Res. 2017. [Epub ahead of print].
13. Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in Cancer. Nat Rev Cancer. 2018;18:5–18.
14. J P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22:8301–41.
15. Gutschner T, Hamerle M, Diederichs S. MALAT1 – a paradigm for long noncoding RNA function in cancer. J Mol Med (Berl). 2013;91:791–801.
16. Wu Y, Huang C, Meng X, Li JJ. Long noncoding RNA MALAT-1: insights into its biogenesis and implications in human disease. Curr Pharm Des. 2015;21: 5017–28.
17. Han X, Yang F, Cao H, Liang Z. Malat1 regulates serum response factor through miR-133 as a competing endogenous RNA in myogenesis. FASEB J. 2015;29:3054–64.
18. Lei R, Xue M, Zhang L, Lin Z. Long noncoding RNA MALAT1-regulated microRNA-506 modulates ovarian cancer growth by targeting lASp. Onco Targets Ther. 2017;10:335–8.
19. Vannini I, Fanini F, Fabbrini M. Emerging roles of microRNAs in Cancer. Curr Opin Genet Dev. 2018;48:128–33.
20. Wang Y, Wang L, Chen C, Chu X. New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications. Mol Cancer. 2018;17:22.
21. Leucci E, Patella F, Waage J, Holmstrom K, Porse B, et al. microRNA-9 targets the long non-coding RNA MALAT1 for degradation in the nucleus. Sci Rep. 2013;3:2535.
22. Wang Y, Wang L, Chen C, Chu X. New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications. Mol Cancer. 2018;17:22.
23. Leucci E, Patella F, Waage J, Holmstrom K, Lindow M, Porse B, et al. microRNA-9 targets the long non-coding RNA MALAT1 for degradation in the nucleus. Sci Rep. 2013;3:2535.